Cyclo Therapeutics (CYTH) Stock Forecast, Price Target & Predictions

CYTH Stock Forecast

Cyclo Therapeutics stock forecast is as follows: an average price target of $0.95 (represents a 50.79% upside from CYTH’s last price of $0.63) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

CYTH Price Target

The average price target for Cyclo Therapeutics (CYTH) is $0.95 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $0.95 to $0.95. This represents a potential 50.79% upside from CYTH's last price of $0.63.

CYTH Analyst Ratings

Buy

According to 5 Wall Street analysts, Cyclo Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CYTH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 2 'Hold' (40.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Cyclo Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 26, 2024	Lucas Ward	Ascendiant	$0.95	$0.78	21.79%	50.79%

The latest Cyclo Therapeutics stock forecast, released on Aug 26, 2024 by Lucas Ward from Ascendiant, set a price target of $0.95, which represents a 21.79% increase from the stock price at the time of the forecast ($0.78), and a 50.79% increase from CYTH last price ($0.63).

Cyclo Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$0.95
Last Closing Price	$0.63	$0.63	$0.63
Upside/Downside	-100.00%	-100.00%	50.79%

In the current month, the average price target of Cyclo Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cyclo Therapeutics's last price of $0.63. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 26, 2024	Ascendiant	Buy	Buy	Hold
Aug 23, 2024	H.C. Wainwright		Neutral	Downgrade
Sep 27, 2023	Morgan Stanley		Underweight	Downgrade
Sep 27, 2023	Maxim Group		Buy	Upgrade
Mar 21, 2023	Bernstein		Market Perform	Initialise

Cyclo Therapeutics's last stock rating was published by Ascendiant on Aug 26, 2024. The company gave CYTH a "Buy" rating, the same as its previous rate.

Cyclo Therapeutics Financial Forecast

Cyclo Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Dec 19
Revenue	-	-	-	-	-	-	-	-	-	$495.48K	$117.12K	$152.41K	$186.80K	$452.17K	$541.89K	$194.90K	$585.12K	$403.92K	$238.59K	$358.13K	$145.59K	$227.36K
Avg Forecast	$400.00K	$600.00K	$100.00K	$200.00K	$543.00K	$294.00K	$267.50K	$376.67K	$169.00K	$141.00K	$183.00K	$380.00K	$642.00K	$618.00K	$571.00K	$547.00K	$393.00K	$382.00K	$360.00K	$278.00K	$250.00K	$300.00K
High Forecast	$606.43K	$909.65K	$151.61K	$266.67K	$775.71K	$445.73K	$267.75K	$376.83K	$256.22K	$150.91K	$277.44K	$576.11K	$973.32K	$618.00K	$571.00K	$547.00K	$393.00K	$382.00K	$360.00K	$278.00K	$250.00K	$300.00K
Low Forecast	$207.72K	$311.57K	$51.93K	$133.33K	$310.29K	$152.67K	$267.25K	$376.50K	$87.76K	$131.09K	$95.03K	$197.33K	$333.38K	$618.00K	$571.00K	$547.00K	$393.00K	$382.00K	$360.00K	$278.00K	$250.00K	$300.00K
# Analysts	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	3.51%	0.64%	0.40%	0.29%	0.73%	0.95%	0.36%	1.49%	1.06%	0.66%	1.29%	0.58%	0.76%

Cyclo Therapeutics's average Quarter revenue forecast for Dec 23 based on 1 analysts is $169.00K, with a low forecast of $87.76K, and a high forecast of $256.22K. CYTH's average Quarter revenue forecast represents a -65.89% decrease compared to the company's last Quarter revenue of $495.48K (Sep 23).

Cyclo Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Dec 19
# Analysts	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$-4.76M	$-4.62M	$-5.00M	$-4.96M	$-4.24M	$-3.46M	$-3.09M	$-2.79M	$-3.86M	$-3.59M	$-4.03M	$-2.68M	$-2.63M
Avg Forecast	$-400.00K	$-600.00K	$-100.00K	$-200.00K	$-543.00K	$-294.00K	$-267.50K	$-376.67K	$-169.00K	$-141.00K	$-183.00K	$-380.00K	$-642.00K	$-618.00K	$-571.00K	$-3.85T	$-393.00K	$-382.00K	$-360.00K	$-278.00K	$-250.00K	$-300.00K
High Forecast	$-207.72K	$-311.57K	$-51.93K	$-133.33K	$-310.29K	$-152.67K	$-267.25K	$-376.50K	$-87.76K	$-131.09K	$-95.03K	$-197.33K	$-333.38K	$-618.00K	$-571.00K	$-3.08T	$-393.00K	$-382.00K	$-360.00K	$-278.00K	$-250.00K	$-300.00K
Low Forecast	$-606.43K	$-909.65K	$-151.61K	$-266.67K	$-775.71K	$-445.73K	$-267.75K	$-376.83K	$-256.22K	$-150.91K	$-277.44K	$-576.11K	$-973.32K	$-618.00K	$-571.00K	$-4.62T	$-393.00K	$-382.00K	$-360.00K	$-278.00K	$-250.00K	$-300.00K
Surprise %	-	-	-	-	-	-	-	-	-	33.75%	25.27%	13.16%	7.73%	6.87%	6.05%	0.00%	7.09%	10.09%	9.98%	14.51%	10.70%	8.78%

undefined analysts predict CYTH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cyclo Therapeutics's previous annual EBITDA (undefined) of $NaN.

Cyclo Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Dec 19
# Analysts	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	$-4.77M	$-4.64M	$-5.01M	$-4.81M	$-4.25M	$-3.45M	$162.86B	$-2.79M	$-3.86M	$-3.60M	$-4.04M	$-2.68M	$-2.64M
Avg Forecast	$-6.32M	$-6.03M	$-6.32M	$-3.61M	$-3.45M	$-4.50M	$-4.45M	$-5.55M	$-6.03M	$-7.76M	$-14.08M	$-12.07M	$-7.18M	$-10.60M	$-9.74M	$-3.64T	$-10.31M	$-10.02M	$-18.90M	$-11.17M	$-5.73M	$-28.64M
High Forecast	$-2.37M	$-2.26M	$-2.37M	$-2.05M	$-3.08M	$-1.69M	$-1.67M	$-2.08M	$-2.26M	$-2.91M	$-5.28M	$-4.53M	$-2.69M	$-10.60M	$-9.74M	$-2.91T	$-10.31M	$-10.02M	$-18.90M	$-11.17M	$-5.73M	$-28.64M
Low Forecast	$-10.56M	$-10.08M	$-10.56M	$-5.17M	$-3.63M	$-7.52M	$-7.44M	$-9.28M	$-10.08M	$-12.96M	$-23.52M	$-20.16M	$-12.00M	$-10.60M	$-9.74M	$-4.37T	$-10.31M	$-10.02M	$-18.90M	$-11.17M	$-5.73M	$-28.64M
Surprise %	-	-	-	-	-	-	-	-	-	0.62%	0.33%	0.41%	0.67%	0.40%	0.35%	-0.04%	0.27%	0.39%	0.19%	0.36%	0.47%	0.09%

Cyclo Therapeutics's average Quarter net income forecast for Jun 22 is $-9.74M, with a range of $-9.74M to $-9.74M. CYTH's average Quarter net income forecast represents a -100.01% decrease compared to the company's last Quarter net income of $162.86B (Mar 22).

Cyclo Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Dec 19
# Analysts	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$1.53M	$1.28M	$1.75M	$1.95M	$1.80M	$2.04M	$2.02M	$1.86M	$2.40M	$1.16M	$1.10M	$1.57M	$895.24K
Avg Forecast	$1.89M	$2.83M	$472.48K	$944.96K	$2.57M	$1.39M	$1.26M	$1.78M	$798.49K	$666.19K	$864.63K	$1.80M	$3.03M	$2.53M	$2.34M	$2.24M	$1.61M	$1.57M	$1.48M	$1.14M	$1.02M	$1.23M
High Forecast	$2.87M	$4.30M	$716.31K	$1.26M	$3.67M	$2.11M	$1.27M	$1.78M	$1.21M	$713.01K	$1.31M	$2.72M	$4.60M	$2.53M	$2.34M	$2.24M	$1.61M	$1.57M	$1.48M	$1.14M	$1.02M	$1.23M
Low Forecast	$981.42K	$1.47M	$245.35K	$629.97K	$1.47M	$721.34K	$1.26M	$1.78M	$414.65K	$619.38K	$449.00K	$932.35K	$1.58M	$2.53M	$2.34M	$2.24M	$1.61M	$1.57M	$1.48M	$1.14M	$1.02M	$1.23M
Surprise %	-	-	-	-	-	-	-	-	-	2.29%	1.47%	0.97%	0.64%	0.71%	0.87%	0.90%	1.16%	1.53%	0.79%	0.96%	1.53%	0.73%

Cyclo Therapeutics's average Quarter SG&A projection for Dec 23 is $798.49K, based on 1 Wall Street analysts, with a range of $414.65K to $1.21M. The forecast indicates a -47.77% fall compared to CYTH last annual SG&A of $1.53M (Sep 23).

Cyclo Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Dec 19
# Analysts	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	$-0.29	$-0.33	$-0.46	$-0.76	$-0.50	$-0.41	$19.36K	$-0.43	$-0.60	$-0.56	$-0.76	$-0.50	$-2.18
Avg Forecast	$-0.22	$-0.21	$-0.22	$-0.13	$-0.12	$-0.16	$-0.15	$-0.19	$-0.21	$-0.27	$-0.49	$-0.42	$-0.25	$-0.37	$-0.34	$-0.33	$-0.36	$-0.35	$-0.66	$-0.39	$-0.20	$-1.00
High Forecast	$-0.08	$-0.08	$-0.08	$-0.07	$-0.11	$-0.06	$-0.06	$-0.07	$-0.08	$-0.10	$-0.18	$-0.16	$-0.09	$-0.37	$-0.34	$-0.33	$-0.36	$-0.35	$-0.66	$-0.39	$-0.20	$-1.00
Low Forecast	$-0.37	$-0.35	$-0.37	$-0.18	$-0.13	$-0.26	$-0.26	$-0.32	$-0.35	$-0.45	$-0.82	$-0.70	$-0.42	$-0.37	$-0.34	$-0.33	$-0.36	$-0.35	$-0.66	$-0.39	$-0.20	$-1.00
Surprise %	-	-	-	-	-	-	-	-	-	1.07%	0.67%	1.10%	3.04%	1.35%	1.21%	-58670.58%	1.19%	1.71%	0.85%	1.95%	2.51%	2.18%

According to 1 Wall Street analysts, Cyclo Therapeutics's projected average Quarter EPS for Jun 22 is $-0.34, with a low estimate of $-0.34 and a high estimate of $-0.34. This represents a -100.00% decrease compared to CYTH previous annual EPS of $19.36K (Mar 22).

Cyclo Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ASRT	Assertio	$0.93	$3.00	222.58%	Buy
AQST	Aquestive Therapeutics	$3.85	$10.00	159.74%	Buy
IRWD	Ironwood Pharmaceuticals	$3.53	$8.50	140.79%	Buy
CYTH	Cyclo Therapeutics	$0.66	$0.95	43.94%	Buy
AMRX	Amneal Pharmaceuticals	$8.07	$11.50	42.50%	Buy
ITCI	Intra-Cellular Therapies	$86.96	$93.33	7.33%	Buy
LFCR	Lifecore Biomedical	$7.47	$6.50	-12.99%	Buy
PAHC	Phibro Animal Health	$22.34	$18.67	-16.43%	Buy

CYTH Forecast FAQ

Is Cyclo Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Cyclo Therapeutics (CYTH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of CYTH's total ratings.

What is CYTH's price target?

Cyclo Therapeutics (CYTH) average price target is $0.95 with a range of $0.95 to $0.95, implying a 50.79% from its last price of $0.63. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cyclo Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CYTH stock, the company can go up by 50.79% (from the last price of $0.63 to the average price target of $0.95), up by 50.79% based on the highest stock price target, and up by 50.79% based on the lowest stock price target.

Can Cyclo Therapeutics stock reach $1?

CYTH's average twelve months analyst stock price target of $0.95 does not support the claim that Cyclo Therapeutics can reach $1 in the near future.

What are Cyclo Therapeutics's analysts' financial forecasts?

Cyclo Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.48M (high $1.87M, low $1.11M), average EBITDA is $-1.481M (high $-1.107M, low $-1.866M), average net income is $-17.956M (high $-8.527M, low $-27.871M), average SG&A $7M (high $8.82M, low $5.23M), and average EPS is $-0.625 (high $-0.297, low $-0.97). CYTH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.3M (high $1.93M, low $704.55K), average EBITDA is $-1.3M (high $-705K, low $-1.934M), average net income is $-22.284M (high $-9.052M, low $-36.374M), average SG&A $6.14M (high $9.14M, low $3.33M), and average EPS is $-0.776 (high $-0.315, low $-1.266).

Did the CYTH's actual financial results beat the analysts' financial forecasts?

Based on Cyclo Therapeutics's last annual report (Dec 2023), the company's revenue was $1.08M, beating the average analysts forecast of $873K by 23.30%. Apple's EBITDA was $-20.05M, beating the average prediction of $-873K by 2196.68%. The company's net income was $-20.057M, missing the average estimation of $-39.934M by -49.77%. Apple's SG&A was $1.94M, missing the average forecast of $4.12M by -52.88%. Lastly, the company's EPS was $-1.23, missing the average prediction of $-1.39 by -11.51%. In terms of the last quarterly report (Sep 2023), Cyclo Therapeutics's revenue was $495.48K, beating the average analysts' forecast of $141K by 251.40%. The company's EBITDA was $-4.759M, beating the average prediction of $-141K by 3275.00%. Cyclo Therapeutics's net income was $-4.771M, missing the average estimation of $-7.757M by -38.49%. The company's SG&A was $1.53M, beating the average forecast of $666.19K by 129.49%. Lastly, the company's EPS was $-0.29, beating the average prediction of $-0.27 by 7.41%